Drug Type Biosimilar, Monoclonal antibody |
Synonyms rituximab biosimilar(Zenotech Laboratories Ltd.) |
Target |
Mechanism CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), CD20-directed cytolytic effects + [1] |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date IN (01 Feb 2013), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Non-Hodgkin Lymphoma | IN | 01 Feb 2013 |
Not Applicable | - | (zqlbkvbtbo) = uutimeurfy dbilkjydlc (abohoxfmck, 69.1 - 74.3) | - | 12 May 2022 | |||
(zqlbkvbtbo) = rkprcwzxcn dbilkjydlc (abohoxfmck, 69.3 - 74.9) |